B
Bull
Bull · 25%TVTX
$24.24
Scenario price
$53.270
+1.513 (+2.84%)At close
Loading chart…
- High
- 53.940
- Open
- 51.610
- VWAP
- 52.91
- Volume
- 2.06M
- Mkt Cap
- 630.35M
- Low
- 51.530
- Amount
- 109.06M
- EV/EBITDA, TTM
- 60.01
Travere Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on identifying, developing, and delivering life-changing therapies to people living with rare kidney and metabolic diseases. Its product, FILSPARI (sparsentan), is indicated to reduce proteinuria in adults with primary IgAN at risk of rapid disease progression. FILSPARI is an oral, once-daily, non-immunosuppressive medication that directly targets glomerular injury in the kidney. Sparsentan is also in late-stage development for focal segmental glomerulosclerosis (FSGS). The Company’s Pegtibatinase is a novel investigational human enzyme replacement candidate being evaluated for the treatment of classical homocystinuria (HCU), which is a rare metabolic disorder. Its commercial products, Thiola and Thiola EC, are for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.
AI analysis of Travere Therapeutics Inc (TVTX)
BuyTravere Therapeutics Inc is a good buy right now due to its strong revenue growth of 48% year-over-year in Q2 2026, reaching $169 million, and a current price of $52.125, which is significantly lower than the analyst price target of $89. However, the company reported a net loss of $34.79 million in Q2 2026, which is a risk to consider.
Valuation Metrics
The current forward P/E ratio for Travere Therapeutics Inc (TVTX) is 39.84, compared to its 5-year average forward P/E of 49.20.
Alphio AI Price Scenarios for TVTX
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.
Whales holding TVTX
Events Timeline
News
5.010-12NewsfilterTravere Grants 178,580 Shares to New Employees
- 8.510-02Newsfilter
FILSPARI Shows Breakthrough Results in Kidney Disease Treatment
7.009-30PRnewswireKuehnLaw Investigates Travere Executives for Fiduciary Breaches
- 1.009-17Newsfilter
Travere Therapeutics to Present at Stifel 2026 Virtual Immunology Forum
- 5.009-11Newsfilter
Travere Grants Inducement Equity to New Employees
TVTX FAQ — answered by Alphio AI
Travere Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on identifying, developing, and delivering life-changing therapies to people living with rare kidney and metabolic diseases. Its product, FILSPARI (sparsentan), is indicated to reduce proteinuria in adults with primary IgAN at risk of rapid disease progression. FILSPARI is an oral, once-daily, non-immunosuppressive medication that directly targets glomerular injury in the kidney. Sparsentan is also in late-stage development for focal segmental glomerulosclerosis (FSGS). The Company’s Pegtibatinase is a novel investigational human enzyme replacement candidate being evaluated for the treatment of classical homocystinuria (HCU), which is a rare metabolic disorder. Its commercial products, Thiola and Thiola EC, are for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).
Travere Therapeutics Inc is a good buy right now due to its strong revenue growth of 48% year-over-year in Q2 2026, reaching $169 million, and a current price of $52.125, which is significantly lower than the analyst price target of $89. However, the company reported a net loss of $34.79 million in Q2 2026, which is a risk to consider.
Community
More ↗No posts yet
Sign up or log in to join the discussionThis page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.